
Justin LaPorte, PharmD, BCOP, offers closing remarks following discussion on the administration of bispecific antibodies.

Your AI-Trained Oncology Knowledge Connection!


Justin LaPorte, PharmD, BCOP, offers closing remarks following discussion on the administration of bispecific antibodies.

A clinical pharmacist explains how their practice has evolved related to the administration of bispecific T-cell engagers.

Justin LaPorte, PharmD, BCOP, presents information on the grading and management of early and late adverse events.

Discussion of the roles and responsibilities of the health care provider (physician, APP), pharmacy staff, nursing staff, and financial counselors/clinic financial manager in bispecific engager administration.

Justin LaPorte, PharmD, BCOP, further explores his experience in developing and/or executing program development and SOPs for bispecific engagers.

A description and overview of the bispecific engager administration program at Northside Hospital.

Justin LaPorte, PharmD, BCOP, introduces the purpose and objectives for the program.